Genetic Mutation Linked to Crohn's and Parkinson's Diseases
The inflammatory bowel diseases IBD are composed of two major subtypes Crohns disease CD and ulcerative colitis UC which are...
View ArticleEurope Immunology Drugs Market Report Suite 2017 ResearchAndMarkets.com
The "Europe Market Report Suite for Immunology Drugs 2017 MedSuite" report has been added to ResearchAndMarkets.com's offering. Besides the typical market data found above you will be able to discover...
View ArticleCell Science Systems CEO to Present at Transforming Healthcare Conference
Roger Deutsch CEO of Cell Science Systems Corp CSS headquartered in Deerfield Beach Florida will speak at the upcoming Navigating Healthcare Transformation Value Based Care The Patient and the...
View ArticleRecommendations for Reporting Imaging Findings in Small Bowel Crohn Disease
An expert consensus guideline for evaluating and interpreting results of computed tomography enterography and magnetic resonance enterography
View ArticleBRIC Market Report Suite for Immunology Drugs 2017 ResearchAndMarkets.com
The "BRIC Market Report Suite for Immunology Drugs 2017 MedSuite" report has been added to ResearchAndMarkets.com's offering. Besides the typical market data found above you will be able to discover...
View ArticleObesity increases risk for surgery in patients with ulcerative colitis
Amanda M. LynnPatients with ulcerative colitis who have a higher BMI are at increased risk for bowel resection according to research presented at the Crohns & Colitis Congress.Amanda M. Lynn MD...
View ArticlePhase III IMmotion151 Study Showed Genentechs TECENTRIQ Atezolizumab and...
TECENTRIQ and Avastin met coprimary endpoint of investigatorassessed progressionfree survival PFS compared with sunitinib for people whose disease expressed PDL1 IMmotion151 is the second Phase III...
View ArticleThe Lawsuit against ViaDerma Inc. has been Dismissed in US District Federal...
LOS ANGELES CAMarketwired February 06 2018 ViaDerma Inc. OTC PINK VDRM a specialty pharmaceutical company devoted to bringing new products to market recently announced today that the Company's legal...
View ArticleSearching for targeted treatments for inflammatory diseases
Inflammatory diseases such as Crohn's disease and multiple sclerosis have been linked to faults in a critical immune pathway that enables inflammation to continue unchecked. Researchers have shed new...
View ArticleuBiome the Leader in Microbial Genomics Launches New Research Study Allowing...
SmartGut patients can now join a research study to learn about how diet and lifestyle factors relate to the microbiome and gut conditions like inflammatory bowel disease irritable bowel syndrome Crohns...
View ArticleBroken immune pathway could cause inflammatory diseases
Scientists at the Walter and Eliza Hall Institute WEHI have linked inflammatory diseases to faults in a critical immune pathway that enables inflammation to continue unchecked. The pathway in question...
View ArticleJanssen to Codevelop Theravance's TD1473 in $1B Collaboration
Johnson & Johnsons Janssen Biotech will codevelop Theravances TD1473 and related backup compounds for inflammatory intestinal diseases including ulcerative colitis and Crohn&39;s disease...
View ArticleTheravance Banks $100m As J&J Bets Big On IBD Drug
If the JAK inhibitor codenamed TD1473 proves effective in Crohns disease and ulcerative colitis the clinical regulatory and commercial knowhow...&160;&160;
View ArticleJanssen Enters into Collab with Theravance Biopharma for Oral Drug Candidate...
NewsThe Janssen Pharmaceutical Companies of Johnson & Johnson announced their entry into a worldwide collaboration with an affiliate of Theravance Biopharma Inc. to develop TD1473 a firstinclass...
View ArticleTheravance Snares $100M From Janssen in Stomach Drug Deal
Theravance Biopharma is teaming up with Janssen Biotech to develop a group of drugs for intestinal diseases such as ulcerative colitis and Crohns. Dublin Ireland basedTheravance Biopharma NASDAQ TBPH...
View ArticleTBPH Inks $1Bln Deal SGMO Hits Yearly High ANAB Is Back Again
Theravance Biopharma has entered into a global codevelopment and commercialization agreement with Johnson & Johnson's Janssen Biotech for TD1473 and related backup compounds for inflammatory...
View ArticleJanssen to codevelop Theravance's TD1473 in $1bn deal
Janssen Biotech will codevelop Theravances TD1473 and associated backup compounds for inflammatory intestinal diseases including ulcerative colitis and Crohn's disease through an agreement that is...
View ArticleInternational research collaboration finds genetic mutation linked to Crohn's...
A genetic mutation was found to be associated with Crohn's disease. The discovery was made by international research collaboration and was published in the prestigious journal Science Translational...
View ArticleTheravance Ireland signs deal with Janssen Biotech
Theravance Biopharma Ireland has signed a global codevelopment and commercialisation deal with Janssen Biotech focusing on new treatments for inflammatory intestinal conditions including ulcerative...
View Article